Enlimomab

N/A

Report date: 2023/04/25 14:17:04

Base Information

Drug NameEnlimomab
Drug Alias Name恩莫单抗RR1/1Murine anti-ICAM-1 monoclonal antibodyBIRR 0001R6 5 D6 +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionIntercellular adhesion molecule-1 inhibitorsImmunosuppressants
TargetsIntercellular adhesion molecule-1
Therapy Area/IndicationsRejection of renal transplantationBurnsGraft vs Host Disease +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Active IndicationsN/A
Inactive IndicationsRejection of renal transplantationBurnsGraft vs Host Disease +[10] 

Other Information

ATC CodeN/A
Related LinksN/A